Additional file 1 of Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

van Marcke, C.; Honoré, N.; van der Elst, A.; Beyaert, S.; Derouane, F.; Dumont, C.; Aboubakar Nana, F.; Baurain, J. F.; Borbath, I.; Collard, P.; Cornélis, F.; De Cuyper, A.; Duhoux, F. P.; Filleul, B.; Galot, R.; Gizzi, M.; Mazzeo, F.; Pieters, T.; Seront, E.; Sinapi, I.; Van den Eynde, M.; Whenham, N.; Yombi, J. C.; Scohy, A.; van Maanen, A.; Machiels, J. P.

doi:10.6084/m9.figshare.14634033.v1

12885_2021_8349_MOESM1_ESM.docx (58.39 kB)

Additional file 1 of Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

journal contribution

posted on 2021-05-21, 03:41 authored by C. van Marcke, N. Honoré, A. van der Elst, S. Beyaert, F. Derouane, C. Dumont, F. Aboubakar Nana, J. F. Baurain, I. Borbath, P. Collard, F. Cornélis, A. De Cuyper, F. P. Duhoux, B. Filleul, R. Galot, M. Gizzi, F. Mazzeo, T. Pieters, E. Seront, I. Sinapi, M. Van den Eynde, N. Whenham, J. C. Yombi, A. Scohy, A. van Maanen, J. P. Machiels

Additional file 1: Table S1. Characteristics of patients who had SARS-CoV-2 RT-PCR. Table S2. Characteristics of patients diagnosed by SARS-CoV-2 serology (SARS-CoV-2 RT-PCR not performed or negative). Table S3. Adverse events with systemic therapy in the population with RT-PCR results. Table S4. Adverse events with systemic therapy in the population without or with negative RT-PCR results. Table S5. Landscape of treatment regimens the patients received and the number of grade 3–4 hematological adverse events, according to the SARS-CoV-2 status. Supplementary appendix 1: Framework used to notify adverse events at each cycle of anti-cancer treatment.